Study of HLX43 alone or with immunotherapy for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new drug, HLX43, by itself or combined with other immunotherapy drugs for people with advanced triple-negative breast cancer (TNBC) that has spread or cannot be removed by surgery. The goal is to see if these treatments can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have advanced TNBC that has spread or cannot be removed by surgery, and you have not had prior treatment for this stage of cancer (or you have had at least one prior treatment if you are in a specific part of the study).
- You must have a tumor that can be measured on a scan, and it must not be in an area that was previously treated with radiation (unless it has grown after radiation).
- You must provide a sample of your tumor tissue for testing, either from a previous biopsy or a new one.
- You must have recovered from the side effects of any prior treatments (like chemotherapy or surgery), and at least 3 weeks must have passed since major treatments.
- You must be in good general health (able to do your daily activities) and have adequate organ function (kidney, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called HLX43 for people whose breast cancer has continued to grow after hormone therapy. The goal is to see if HLX43 can help shrink or control the cancer.
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
This trial tests a new combination of two drugs for people with advanced lung cancer that has worsened after previous treatments like chemotherapy or immunotherapy. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a new drug called HLX43 (an antibody-drug conjugate targeting PD-L1) for people with advanced stomach or gastroesophageal junction cancer that has progressed after at least one prior treatment. It aims to see if it can shrink tumors and help patients live longer.
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
Hear when a new Breast Cancer (Triple Negative Breast Cancer (TNBC)) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.